DE69941719D1 - Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden - Google Patents
Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurdenInfo
- Publication number
- DE69941719D1 DE69941719D1 DE69941719T DE69941719T DE69941719D1 DE 69941719 D1 DE69941719 D1 DE 69941719D1 DE 69941719 T DE69941719 T DE 69941719T DE 69941719 T DE69941719 T DE 69941719T DE 69941719 D1 DE69941719 D1 DE 69941719D1
- Authority
- DE
- Germany
- Prior art keywords
- present
- mage
- ctl clones
- isolated
- ctl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000607734 Yersinia <bacteria> Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/165,863 US6407063B1 (en) | 1998-10-02 | 1998-10-02 | Tumor antigens and CTL clones isolated by a novel procedure |
US09/289,350 US6531451B1 (en) | 1998-10-02 | 1999-04-09 | Tumor antigens and CTL clones isolated by a novel procedure |
PCT/IB1999/001664 WO2000020445A2 (en) | 1998-10-02 | 1999-09-15 | Tumor antigens and ctl clones isolated by a novel procedure |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69941719D1 true DE69941719D1 (de) | 2010-01-07 |
Family
ID=22600796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69941719T Expired - Lifetime DE69941719D1 (de) | 1998-10-02 | 1999-09-15 | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden |
Country Status (4)
Country | Link |
---|---|
US (2) | US6407063B1 (de) |
JP (1) | JP4722289B2 (de) |
AT (1) | ATE449787T1 (de) |
DE (1) | DE69941719D1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69533295T3 (de) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
AU5810201A (en) * | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US7786278B2 (en) * | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
WO2004037284A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
EP1697399B1 (de) | 2003-12-12 | 2016-11-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1 |
JP2008505106A (ja) * | 2004-07-01 | 2008-02-21 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | ハイスループットプロテオミクス |
CN101041816B (zh) * | 2006-12-01 | 2010-08-25 | 扬州大学 | 人工抗原递呈细胞及其制备方法 |
US8313894B2 (en) | 2008-07-01 | 2012-11-20 | Genocea Biosciences, Inc. | Antigen screening system |
JP7204484B2 (ja) * | 2016-04-08 | 2023-01-16 | アダプティミューン・リミテッド | T細胞受容体 |
JP2020514378A (ja) | 2017-03-20 | 2020-05-21 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | 処置方法 |
EP3806888B1 (de) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie |
CN114174327A (zh) | 2019-03-08 | 2022-03-11 | 黑曜石疗法公司 | 用于可调整调控的cd40l组合物和方法 |
KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
US20200318068A1 (en) * | 2019-04-04 | 2020-10-08 | Immatics US, Inc. | Use of retinoic acid in t-cell manufacturing |
BR112021025022A2 (pt) | 2019-06-12 | 2022-02-22 | Obsidian Therapeutics Inc | Composições de ca2 e métodos para regulação ajustáveis |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
CN115210250A (zh) | 2020-01-08 | 2022-10-18 | 黑曜石疗法公司 | 用于可调节性调控转录的组合物和方法 |
CN111534546A (zh) * | 2020-05-09 | 2020-08-14 | 赛诺(深圳)生物医药研究有限公司 | 一种具有多等位基因p53编码序列的重组腺病毒的制备方法 |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
IL106610A0 (en) * | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
US5558995A (en) | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
US6328971B1 (en) | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
AU702517B2 (en) * | 1993-08-06 | 1999-02-25 | Epimmune, Inc. | Cloning and characterization of the complete MAGE-1 gene |
WO1997026328A1 (en) * | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US6265215B1 (en) | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
JP2002507397A (ja) * | 1998-03-13 | 2002-03-12 | エピミューン,インコーポレイティド | Hla結合ペプチド及びその使用 |
-
1998
- 1998-10-02 US US09/165,863 patent/US6407063B1/en not_active Expired - Lifetime
-
1999
- 1999-04-09 US US09/289,350 patent/US6531451B1/en not_active Expired - Lifetime
- 1999-09-15 DE DE69941719T patent/DE69941719D1/de not_active Expired - Lifetime
- 1999-09-15 JP JP2000574556A patent/JP4722289B2/ja not_active Expired - Fee Related
- 1999-09-15 AT AT99970091T patent/ATE449787T1/de active
Also Published As
Publication number | Publication date |
---|---|
US6531451B1 (en) | 2003-03-11 |
US6407063B1 (en) | 2002-06-18 |
ATE449787T1 (de) | 2009-12-15 |
JP2003518911A (ja) | 2003-06-17 |
JP4722289B2 (ja) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69941719D1 (de) | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden | |
WO2000020445A3 (en) | Tumor antigens and ctl clones isolated by a novel procedure | |
von Boehmer | The selection of the α, β heterodimeric T-cell receptor for antigen | |
US10968430B2 (en) | Use of specific regulatory T-cells to induce immune tolerance | |
Bozzacco et al. | Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells | |
Kimura et al. | cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2 (+) cytotoxic T lymphocytes | |
Tonegawa | The molecules of the immune system | |
de Koster et al. | T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. | |
Anderson et al. | Fibroblast dependency during early thymocyte development maps to the CD25+ CD44+ stage and involves interactions with fibroblast matrix molecules | |
DK0512112T3 (da) | Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier | |
ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
PT994903E (pt) | Metodos e composicoes para glicoproteinas galactosiladas | |
AR018064A1 (es) | Proteina de fusion que consiste en un antigeno asociado a tumores derivado de la familia mage, secuencia de acido nucleico que la codifica, vector que lo comprende, celula huesped que no puede generar un individuo completo transformada con dicho acido nucleico, vacuna que contiene dicha proteina, su | |
Kohler et al. | Cross‐reactive trinitrophenylated peptides as antigens for class II major histocompatibility complex‐restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire | |
NO963918D0 (no) | Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav | |
BR9809656A (pt) | Composição imunopotencializante | |
CN112639136A (zh) | 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法 | |
Golstein et al. | Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions | |
Bergman et al. | Characterization of H+, K+‐ATPase T cell epitopes in human autoimmune gastritis | |
WAKSMAN | Overview: Biology of the lymphokines | |
TW200611706A (en) | Cytotoxic t lymphocyte | |
Guimezanes et al. | A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product | |
RU2005106841A (ru) | Эпитопы т-клеток в эритропоэтине | |
DE69833455D1 (de) | Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) | |
MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |